We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

    • Bavarian Nordic

    Health

    Calls for Reduced Mpox Testing Prices Amid Global Health Challenges

    Global health advocates are urging Cepheid to reduce mpox test prices from $20 to $5, aiming to improve access in low-income countries like the Democratic Republic of Congo. Recent cases of mpox and bird flu in the U.S. highlight the urgent need for equitable healthcare solutions and enhanced disease surveillance. As the world faces these health challenges, the call for affordable testing and treatment options intensifies.

    Posted on Jhon
    Business

    Bavarian Nordic Reports Revenue Growth and Strategic Advances in Q3 2024

    Bavarian Nordic A/S reports strong interim financial results for the first nine months of 2024, with total revenue reaching DKK 3,622 million and an 18% increase in its Travel Health division. The company maintains its full-year guidance amidst uncertainties related to mpox vaccine logistics, while securing DKK 2,400 million in vaccine orders for 2025. CEO Paul Chaplin highlights the company’s commitment to global health and its proactive measures in combating the mpox outbreak.

    Posted on Jhon
    Health

    Bavarian Nordic Submits Chikungunya Vaccine for Approval in Europe

    Bavarian Nordic has submitted its chikungunya vaccine for approval in Europe, following a similar application in the US. This strategic move aims to combat the spread of the mosquito-borne viral disease and improve global health initiatives. Stay tuned for updates on the potential approval in the first half of 2025.

    Posted on Jhon